PEAK6 Group’s Neurocrine Biosciences NBIX Stock Holding History

PEAK6 Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$285K	Sell	2,900 -42,100	-94%	-$3.77M	﹤0.01%	3060
2018 Q1	$3.73M	Buy	+45,000	New	+$3.8M	0.02%	981
2017 Q3	–	Sell	-5,100	Closed	-$235K	–	4808
2017 Q2	$235K	Buy	+5,100	New	+$247K	﹤0.01%	3212
2016 Q4	–	Sell	-15,000	Closed	-$760K	–	4959
2016 Q3	$760K	Sell	15,000 -12,600	-46%	-$628K	0.01%	2013
2016 Q2	$1.25M	Buy	+27,600	New	+$1.27M	0.01%	1616
2015 Q3	–	Sell	-8,700	Closed	-$416K	–	5427
2015 Q2	$416K	Sell	8,700 -12,600	-59%	-$534K	﹤0.01%	2968
2015 Q1	$846K	Buy	+21,300	New	+$762K	0.01%	2049
2014 Q3	–	Sell	-36,200	Closed	-$537K	–	5000
2014 Q2	$537K	Buy	36,200 +24,300	+204%	+$343K	0.01%	2250
2014 Q1	$192K	Buy	+11,900	New	+$204K	﹤0.01%	3463

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

PEAK6 Group's NBIX Position: Q2 2018 in Review

PEAK6 Group reduced its Neurocrine Biosciences (NBIX) stake by 46% in Q2 2018, selling an estimated $1.03M and leaving 13,649 shares worth $1.34M. The position accounts for 0.01% of the portfolio, ranked #1712.

PEAK6 Group first reported a position in NBIX in Q1 2018 and has held it in 2 quarters since. The position peaked at $2.09M in Q1 2018. 274 funds tracked by Wall St. Rank hold NBIX as of Q2 2018.

PEAK6 Group held 13,649 shares of Neurocrine Biosciences worth $1.34M as of Q2 2018.
PEAK6 Group sold 11,535 Neurocrine Biosciences shares in Q2 2018, an estimated $1.03M.
Neurocrine Biosciences made up 0.01% of PEAK6 Group's portfolio in Q2 2018, its #1712 holding.
PEAK6 Group first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 2 quarters since.
PEAK6 Group's Neurocrine Biosciences position peaked at $2.09M in Q1 2018.
274 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.